Experience

Davis Polk advised MSCI Inc. (“MSCI”) in connection with a Rule 144A/Regulation S offering of $800 million aggregate principal amount of its 5.750% senior notes due 2025. The notes are…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion aggregate principal amount of notes. The notes were issued in…

Davis Polk advised the joint lead arranger and bookrunner, and the administrative agent, in connection with the $650 million senior secured credit facilities (the “Facilities”) provided to…

Davis Polk is advising Tailwind Capital in connection with the sale of ReTrans Inc. to The Kuehne + Nagel Group. The transaction is subject to approval by regulatory authorities. Tailwind…

Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Avid Technology, Inc.(“Avid”) of an aggregate principal amount of $125 million of its 2.00% convertible…

Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Interactive Intelligence Group, Inc. of an aggregate principal amount of $150 million of its 1.25%…

Davis Polk is advising Micrel, Incorporated in connection with its sale to Microchip Technology Incorporated for a total equity value of approximately $839 million. The transaction,…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by CalAmp Corp. of $150 million aggregate principal amount of its 1.625% convertible senior notes due 2020…